|

Liver Disease Clinical Trials in Mesa, AZ

49 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 35 mi
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)—5 mi
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 25 mi
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenPhase 35 mi
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionPhase 28 mi
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)Phase 28 mi
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Phase 38 mi
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPhase 38 mi
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver DiseasePhase 28 mi
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Phase 38 mi
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)Phase 28 mi
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver ProblemsPhase 18 mi
DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis—8 mi
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPhase 38 mi
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)N/A8 mi
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus InfectionPhase 18 mi
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver CirrhoticsPhase 18 mi
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity—8 mi
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).Phase 28 mi
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver TransplantationPhase 28 mi
Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal HypertensionN/A8 mi
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisPhase 38 mi
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisPhase 38 mi
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Phase 1/28 mi
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerPhase 28 mi
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesPhase 18 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—8 mi
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 48 mi
A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 28 mi
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantPhase 28 mi
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaPhase 28 mi
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)—14 mi
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency EmphysemaPhase 214 mi
Fibrosis Lessens After Metabolic SurgeryPhase 414 mi
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPhase 314 mi
Disparities Among Liver Transplant Patients—14 mi
Adverse Outcomes and Mortality in Liver TransplantN/A14 mi
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)Phase 314 mi
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin ProteinPhase 314 mi
Early Tracking of Childhood Health Determinants (ETCHED) Study—14 mi
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaPhase 214 mi
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPhase 114 mi
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaPhase 314 mi
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform—14 mi
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced CancerPhase 114 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 314 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 114 mi
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Phase 226 mi
DESTINY-PANTUMOUR04—37 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.